February 27 - 28, 2017
Keynote Speaker: James P. Allison (University of Texas MD Anderson Cancer Center)
Discover the latest on immunotherapeutic strategies that are currently being employed to treat some of the most devastating forms of cancer from leading experts in immunotherapy.
This event is sold out.
March 15 - 16, 2017
Experience a public-facing dialogue exploring the nuanced ethical and scientific rationale behind randomized controlled clinical trials, accelerated alternatives, and the implications of these discussions on drug approval and patient interests.
Tuesday, April 11, 2017 | 9:00 AM - 5:00 PM
Speakers: Brian Kaspar (Nationwide Children's Hospital), R. Jude Samulski (Bamboo Therapeutics), Barry Byrne (University of Florida, Powell Gene Therapy Center), Maria Escolar (Children's Hospital of Pittsburgh), Jakub Tolar (University of Minnesota), Kevin Flanigan (Nationwide Children's Hospital), Katherine A. High (Spark Therapeutics), and David Pearce (Sanford Research)
Gene therapy has been proposed as a promising therapeutic strategy for monogenic disorders. This symposium will explore recent advances in the field, and identify ongoing obstacles on the path to wider use of this approach.
May 15 - 17, 2017
Keynote Speaker: Vijay K. Kuchroo (Harvard Institutes of Medicine)
Learn about most recent advances in basic, translational, and clinical research on the rare, acquired disorder, Myasthenia Gravis, as well as implications of this research on a range of related autoimmune and neuromuscular diseases.
Friday, October 7, 2016 | 9:00 AM - 5:00 PM
Mental illness causes debilitating consequences on quality of life for individuals, families, and society. This symposium explores avenues for translating these discoveries about the neurobiology of a spectrum of mental illnesses into new treatments.
September 21 - 23, 2016
Featuring: Peder S. Olofsson (Karolinska Institutet) and Kevin J. Tracey (The Feinstein Institute for Medical Research)
Bioelectronic medicine, a new discipline aimed at interfacing electronics with cells to target molecular mechanisms, is at the epicenter of healthcare, technology, and science. This symposium will advance the technological promise of bioelectronics.
Tuesday, June 28, 2016 | 8:00 AM - 5:30 PM
Keynote Speaker: Giancarlo Comi (Università Vita-Salute San Raffaele)
Explore novel and emerging treatments for multiple sclerosis, including biomarkers and MRI usage in disease diagnosis, prognosis, and monitoring.
Tuesday, June 21, 2016 | 8:30 AM - 5:00 PM
Keynote Speaker: Sharon Inouye (Harvard Medical School)
This meeting will convene leading scientists and physicians to discuss the challenges and opportunities to create biomarkers and therapeutics for these patients who are vulnerable to delirium, cognitive decline, and dementia following surgery.
Keynote Speakers: Barry G. Arnason, MD (University of Chicago) and Giancarlo Comi, MD (Università Vita-Salute San Raffaele)
This one-day, translational conference brought together academic and clinical researchers with industry leaders to discuss current therapeutics.
Keynote Speakers: The Honorable Patrick J. Kennedy (Former United States Representative, Rhode Island; Co-Founder, One Mind; and Founder, Kennedy Forum), George F. Koob (National Institute on Alcohol Abuse and Alcoholism, U.S. National Institutes of Health), and Nora D. Volkow (National Institute on Drug Abuse, U.S. National Institutes of Health)
Leading experts, including NIAAA and NIDA directors, discuss the latest on neurobiology of addiction; susceptibility of the teen brain; new treatment strategies; and social, economic, political, and legislative aspects of this disease.
Edited by Annals of the New York Academy of Sciences
This diverse collection of papers discusses topics ranging from a paleobiologic study of the emergence of the diaphragm to changes in gait patterns after acute brain injury.
Featuring: Sharon Inouye (Harvard Medical School)
Surgery helps millions of Americans overcome illness to live longer, healthier lives. Yet surgery can lead to delirium, cognitive decline, and perhaps even a higher long-term risk of dementia for many patients, a risk that is poorly understood and often under-recognized in the clinic. With numerous factors—including age—contributing to each patient's level of risk, what are the challenges and opportunities to creating biomarkers and therapeutics for those who are most vulnerable?